AbbVie's SWOT analysis: stock outlook amid Humira erosion and pipeline growth
AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...
Crain's Chicago Business6h
Two more AbbVie drugs put on the Medicare negotiation list
Other AbbVie drugs, including its once-best-selling multiuse medication Humira, have been targeted by new provisions in the ...
Income & Growth: 3 Of The Best Dividend Stocks For Any Market
Discover how to navigate inflation with long-term investments in resilient companies like Coca-Cola, AbbVie, and TC Energy.
AbbVie stock target cut, keeps Buy rating on growth outlook
Guggenheim Securities adjusted its financial outlook for shares of AbbVie Inc . (NYSE:ABBV), reducing the price target to $212 from the previous $221, while still recommending a Buy rating for the ...
Organon: A Tricky 2025 Awaits, But I'm Happy With A >7% Dividend Yield
Organon has faced significant price volatility and underperformance since its spin-off from Merck. Check out why I recommend ...
Optimistic Outlook on AbbVie’s Emraclidine Strategy: A High-Reward Investment Opportunity
Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the ...
Teva price target raised to $30 from $23 at Piper Sandler
Piper Sandler raised the firm’s price target on Teva (TEVA) to $30 from $23 and keeps an Overweight rating on the shares after meeting with ...